---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-025649"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2026-01-28T23:59:59+00:00"
generated_at: "2026-05-16T06:59:04.909310+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CalciMedica discontinues Phase 2 KOURAGE trial of Auxora in AKI after IDMC safety concern

## Summary
- IDMC identified a safety concern requiring re-evaluation of study design, particularly enrollment criteria.
- No treatment-related deaths or SAEs requiring expedited FDA reporting in the trial.
- Company plans comprehensive review of unblinded data to inform possible future AKI trials.
- CEO reaffirms optimism for Auxora in acute pancreatitis; pivotal trial design expected H1 2026.
- Also advancing second CRAC inhibitor CM5480 for pulmonary arterial hypertension.

## SEC filing metadata
- accession: 0001193125-26-025649
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2026-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312526025649/0001193125-26-025649-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312526025649/d55769d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-025649
- JSON: https://secwatch.observer/filing/0001193125-26-025649.json
- Plain text: https://secwatch.observer/filing/0001193125-26-025649.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.